# Saturn V Capital Management LP: Form 13F holdings

An institutional investment manager in AUSTIN, TX. SEC CIK 1964437.

- Quarter ended: 2026-06-30
- Filed: 2026-08-14
- Reported value: $697.5m
- Positions: 23 (23 lines in the filing's table; lines for the same security and option type are added together here)
- Compared with: the 13F for the quarter ended 2026-03-31
- Filing: https://www.sec.gov/Archives/edgar/data/1964437/000196443726000012/

## Holdings

As filed, largest first. Reported value is what the manager stated at the quarter end (Jun 30, 2026), in US dollars; it is filing data, not a price. Weight is the share of the total reported value.

| Issuer | Class | Reported value | Weight | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | ---: | --- | --- |
| [AMYLYX PHARMACEUTICALS INC (AMLX)](/companies/amlx.md) | COM | $83.0m | 11.9% | 4,624,101 |  | Added +274,216 |
| [ALUMIS INC (ALMS)](/companies/alms.md) | COM | $82.0m | 11.8% | 2,915,443 |  | Reduced −286,632 |
| [ABIVAX SA (ABVX)](/companies/abvx.md) | SPONSORED ADS | $69.1m | 9.9% | 518,865 |  | Reduced −23,831 |
| [VAXCYTE INC (PCVX)](/companies/pcvx.md) | COM | $49.6m | 7.1% | 852,914 |  | Added +28,382 |
| [IMMIX BIOPHARMA INC (IMMX)](/companies/immx.md) | COM | $48.0m | 6.9% | 4,658,429 |  | Added +964,844 |
| PHARVARIS N V | COM | $45.4m | 6.5% | 1,314,122 |  | Added +112,720 |
| JAZZ PHARMACEUTICALS PLC | SHS USD | $38.8m | 5.6% | 160,938 |  | Reduced −2,023 |
| [CELCUITY INC (CELC)](/companies/celc.md) | COM | $38.7m | 5.6% | 370,318 |  | Added +88,414 |
| [DISC MEDICINE INC (IRON)](/companies/iron.md) | COM | $38.4m | 5.5% | 524,730 |  | Added +74,804 |
| [CANDEL THERAPEUTICS INC (CADL)](/companies/cadl.md) | COM | $34.0m | 4.9% | 3,303,686 |  | Added +407,098 |
| [X4 PHARMACEUTICALS INC (XFOR)](/companies/xfor.md) | COM NEW | $32.6m | 4.7% | 6,973,343 |  | Added +516,697 |
| [MONOPAR THERAPEUTICS INC (MNPR)](/companies/mnpr.md) | COM NEW | $28.9m | 4.1% | 311,976 |  | Reduced −33,650 |
| [DYNE THERAPEUTICS INC (DYN)](/companies/dyn.md) | COM | $23.5m | 3.4% | 1,057,493 |  | Added +90,884 |
| [TREVI THERAPEUTICS INC (TRVI)](/companies/trvi.md) | COM | $19.6m | 2.8% | 1,052,043 |  | New +1,052,043 |
| ZURA BIO LTD | CLASS A ORD SHS | $12.4m | 1.8% | 2,101,119 |  | Added +1,361,159 |
| [SAGIMET BIOSCIENCES INC (SGMT)](/companies/sgmt.md) | COM SER A | $11.4m | 1.6% | 1,479,918 |  | New +1,479,918 |
| OCULIS HOLDING AG | ORDINARY SHARES | $9.5m | 1.4% | 684,880 |  | Added +168,119 |
| [INHIBIKASE THERAPEUTICS INC (IKT)](/companies/ikt.md) | COM NEW | $7.9m | 1.1% | 3,869,056 |  | Added +5,611 |
| [VIR BIOTECHNOLOGY INC (VIR)](/companies/vir.md) | COM | $7.9m | 1.1% | 770,643 |  | New +770,643 |
| [INVIVYD INC (IVVD)](/companies/ivvd.md) | COM | $7.3m | 1.0% | 8,392,288 |  | Reduced −2,556,796 |
| [ALTO NEUROSCIENCE INC (ANRO)](/companies/anro.md) | COM SHS | $4.8m | 0.7% | 182,829 |  | Added +93,830 |
| [SATELLOS BIOSCIENCE INC (MSLE)](/companies/msle.md) | COM | $2.7m | 0.4% | 350,000 |  | Unchanged |
| [OVID THERAPEUTICS INC (OVID)](/companies/ovid.md) | COM | $1.8m | 0.3% | 663,060 |  | Reduced −3,503,606 |

## Sold out

Held at the end of the quarter before and not reported this quarter.

| Issuer | Class | Reported value | Weight | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | ---: | --- | --- |
| [COGENT BIOSCIENCES INC (COGT)](/companies/cogt.md) | COM | $0 | 0.0% | 0 |  | Sold out −626,635 |

Source: SEC EDGAR, Form 13F-HR, accession 0001964437-26-000012. Last ingested by Listed: Oct 22, 2026, 05:26 ET. No prices; not investment advice.